Cosponsor
Sign in

S 1097 · introduced · significant

Interagency Patent Coordination and Improvement Act of 2025

What this bill does

  • Creates a task force to improve coordination between the Patent Office and FDA on drug and biotech patents.
  • Affects patent examiners, drug manufacturers, and FDA staff handling new drug approvals.
  • No direct cost specified; agencies share information and coordinate existing processes.

Generated by claude-haiku-4-5

Community Threads

Started by Cosponsor

  1. 01

    How might better coordination between the Patent Office and FDA reduce delays in drug approval timelines for manufacturers and patients?

  2. 02

    What safeguards should prevent shared patent information between agencies from being misused or creating conflicts of interest?

  3. 03

    Which stakeholders—patients, generic drug makers, or brand manufacturers—would benefit most from improved patent and FDA approval coordination?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.

Sponsor · D-IL

Richard J. Durbin

Citizen cosponsors

0

In Congress

4/ 100

Senators cosponsoring

Introduced 2025-04-10

Joining the bill

Legislative timeline

  1. 2025-04-10 · senate · Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

  2. 2025-04-10 · senate · Committee

    Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

  3. 2025-04-10 · Committee

    Committee on the Judiciary. Reported by Senator Grassley with amendments. Without written report.

  4. 2025-04-03 · senate · Committee

    Committee on the Judiciary. Ordered to be reported with amendments favorably.

  5. 2025-03-24 · senate · IntroReferral

    Read twice and referred to the Committee on the Judiciary. (text: CR S1804-1805)

  6. 2025-03-24 · IntroReferral

    Introduced in Senate

Congress.gov ↗

Citizen comments

Sign in to comment on this bill.

No comments yet — be the first.